Outcomes of Peginterferon Alpha-2a and Ribavirin Hepatitis C therapy in Aboriginal Canadians

Curtis L Cooper; Robert J Bailey; Vince G Bain; Frank Anderson; Eric M Yoshida; Mel Krajden; Paul Marotta; for the Canadian Pegasys Study Group

doi:10.1155/2008/320150

Canadian Journal of Gastroenterology (Jan 2008)

Outcomes of Peginterferon Alpha-2a and Ribavirin Hepatitis C therapy in Aboriginal Canadians

Curtis L Cooper,
Robert J Bailey,
Vince G Bain,
Frank Anderson,
Eric M Yoshida,
Mel Krajden,
Paul Marotta,
for the Canadian Pegasys Study Group

Affiliations

Curtis L Cooper: University of Ottawa, Ottawa, Ontario, Canada
Robert J Bailey: Royal Alexandra Hospital, Canada
Vince G Bain: University of Alberta, Edmonton, Alberta, Canada
Frank Anderson: The Liver and Intestinal Research Centre, Canada
Eric M Yoshida: Vancouver Hospital Health Sciences Centre, Canada
Mel Krajden: BC Centre for Disease Control, Vancouver, British Columbia, Canada
Paul Marotta: University of Western Ontario, London, Ontario, Canada
for the Canadian Pegasys Study Group

DOI: https://doi.org/10.1155/2008/320150
Journal volume & issue: Vol. 22, no. 8
pp. 677 – 680

Abstract

Read online

BACKGROUND: There is little published information on baseline characteristics and therapeutic outcomes in hepatitis C virus (HCV)-infected Aboriginal Canadians. It is unclear what proportion of HCV-infected Aboriginal people receive therapy relative to other populations.

Published in Canadian Journal of Gastroenterology

ISSN: 0835-7900 (Print); 1916-7237 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://onlinelibrary.wiley.com/journal/1720

About the journal